Coastal Bridge Advisors LLC Takes Position in Abbott Laboratories $ABT

Key Points

• Coastal Bridge Advisors initiated a position in Abbott Laboratories during the second quarter, purchasing 11,965 shares valued at approximately $1.09 million. Institutional investors collectively own 75.18% of the company.
• Analysts remain broadly positive, with Abbott carrying a “Moderate Buy” consensus rating and an average price target of $119.50, despite some recent target reductions.
• Abbott exceeded quarterly earnings and revenue expectations, with revenue rising 13% year over year. The company also declared a quarterly dividend of $0.63 per share, equivalent to a 2.3% annualized yield.

Coastal Bridge Advisors LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,965 shares of the healthcare product maker's stock, valued at approximately $1,086,000.

Other hedge funds have also added to or reduced their stakes in the company. Freemont Management S.A. lifted its position in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after buying an additional 7,100 shares during the last quarter. Thrivent Financial for Lutherans grew its position in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock valued at $30,931,000 after acquiring an additional 48,286 shares during the last quarter. Aureus Asset Management LLC raised its stake in Abbott Laboratories by 25.0% during the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock worth $34,078,000 after acquiring an additional 66,422 shares in the last quarter. North Dakota State Investment Board bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $7,439,000. Finally, Thompson Investment Management Inc. lifted its holdings in shares of Abbott Laboratories by 786.0% in the second quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker's stock worth $1,276,000 after acquiring an additional 12,474 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ABT. UBS Group decreased their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Weiss Ratings raised shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Piper Sandler reiterated an "overweight" rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. Finally, Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Price Performance

ABT stock opened at $110.52 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market cap of $191.24 billion, a price-to-earnings ratio of 35.77, a PEG ratio of 2.02 and a beta of 0.59. The company's fifty day simple moving average is $103.83 and its 200 day simple moving average is $100.09. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the business posted $1.26 EPS. The business's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's payout ratio is presently 81.55%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source